Enhanced microglial dynamics and a paucity of tau seeding in the amyloid plaque microenvironment contribute to cognitive resilience in Alzheimer’s disease

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Omics and large cohort dataset analyses have identified potential cell signatures and molecular mechanisms of resilience, including high processing of energetic pathways involving mitochondrial metabolism and glycolysis, axonal and dendritic growth, and a general increase in protein processing.

“Advancements in omics and large cohort dataset analyses have enabled the identification of potential cell signatures and molecular mechanisms of resilience, including high processing of energetic pathways involving mitochondrial metabolism and glycolysis, axonal and dendritic growth, and a general increase in protein processing [11, 90, 91].”

• cites [11] Carlyle BC, Kandigian SE, Kreuzer J, Das S, Trombetta BA, Kuo Y et al (2021) Synaptic proteins associated with cognitive performance and neuropathology in older humans revealed by multiplexed fractionated proteomics. Neurobiol Aging 105:99–114. https://doi.org/10.1016/j.neurobiolaging.2021.04.012 sourceDisputed

  Split into 2 atoms — 0 confirmed, 1 partially supported, 1 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

  Checked by a reasoning model — may be wrong.

  Experimental — accuracy not yet measured
• cites [90] Tandon R, Levey AI, Lah JJ, Seyfried NT, Mitchell CS (2023) Machine learning selection of most predictive brain proteins suggests role of sugar metabolism in Alzheimer’s disease. J Alzheimers Dis 92:411–424. https://doi.org/10.3233/JAD-220683 sourcePartly supported

  Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

  Experimental — accuracy not yet measured
• cites [91] Telpoukhovskaia M, Hadad N, Gurdon B, Dai M, Ouellette AR, Neuner S et al (2022) Conserved cell-type specific signature of resilience to Alzheimer’s disease nominates role for excitatory cortical neurons. Alzheimers Dement. https://doi.org/10.1002/alz.069370 sourceNot checked — no full text of the source

Probably not a substantial claim: may not pass S3 (load-bearing).

Phosphorylation of tau within dystrophic neurites subsequently contributes to the formation of neuritic plaques during AD progression.

“In the context of AD or aging, the formation of filamentous plaques has been associated with the phosphorylation of tau within dystrophic neuritis [13, 53, 106], which subsequently contributes to the formation of neuritic plaques (a subset of Aβ plaques surrounded by and containing dystrophic neurites) during AD progression”

• cites [13] Chen Y, Zhao S, Fan Z, Li Z, Zhu Y, Shen T et al (2021) Metformin attenuates plaque-associated tau pathology and reduces amyloid-β burden in APP/PS1 mice. Alzheimers Res Ther 13:40. https://doi.org/10.1186/s13195-020-00761-9 sourcePartly supported

  The Results report phosphorylated tau particles surrounding Aβ plaques in APP/PS1 mice, supporting the association between tau pathology and plaques. The Discussion instead proposes that existing Aβ plaques induce tau accumulation in surrounding dystrophic neurites; it does not establish that tau phosphorylation forms neuritic plaques during AD progression. (LLM, conf=0.85)

  Experimental — accuracy not yet measured
• cites [53] Li T, Braunstein KE, Zhang J, Lau A, Sibener L, Deeble C et al (2016) The neuritic plaque facilitates pathological conversion of tau in an Alzheimer’s disease mouse model. Nat Commun 7:12082. https://doi.org/10.1038/ncomms12082 sourceDisputed

  The Results section (‘Neuritic plaque is not sufficient for the conversion of tau’) reports that tau was not hyperphosphorylated before neuritic plaques formed. Although the paper confirms phosphorylated tau within dystrophic neurites around plaques, its Discussion proposes the opposite sequence: Aβ-dependent plaque formation provides the environment for tau modification, not that tau phosphorylation subsequently forms the plaques. (LLM, conf=0.90)

  Checked by a reasoning model — may be wrong.

  Experimental — accuracy not yet measured
• cites [106] Yuan P, Condello C, Keene CD, Wang Y, Bird TD, Paul SM et al (2016) TREM2 haplodeficiency in mice and humans impairs the microglia barrier function leading to decreased amyloid compaction and severe axonal dystrophy. Neuron 90:724–739. https://doi.org/10.1016/j.neuron.2016.05.003 sourcePartly supported

  The Results section on tau hyperphosphorylation (page unavailable) reports phospho-tau labeling in dystrophic neurites around filamentous and compact amyloid deposits. It does not show that tau phosphorylation contributes to plaque formation; the Discussion instead describes filamentous plaques as causing axonal dystrophy. (LLM, conf=0.85)

  Experimental — accuracy not yet measured

Classified as probably not a substantial claim.

Aβ plaques and neurofibrillary tau tangles are causally related to the cognitive manifestations of Alzheimer's disease.

“Beta-amyloid (Aβ) plaques and neurofibrillary tau tangles (NFTs) have long been known to be causally related to the cognitive manifestations of Alzheimer’s disease (AD) [19].”

• cites [19] DeTure MA, Dickson DW (2019) The neuropathological diagnosis of Alzheimer’s disease. Mol Neurodegener 14:32. https://doi.org/10.1186/s13024-019-0333-5 sourcePartly supported

  In Background, ‘Pathology of Alzheimer’s disease’ (page not supplied), the review says these lesions lead to neuronal and synaptic loss and AD symptoms. But ‘Neuritic plaques’ calls Aβ-driven cognitive decline a hypothesis, while ‘Distribution of neurofibrillary tangles’ says the relationship between tangles and cell death is not understood. The claim overstates that qualified account as a long-established causal relationship for both lesions. (LLM, conf=0.87)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing).

The area surrounding NFTs in the hippocampus of AsymAD cases exhibits lower levels of proteins associated with inflammation, oxidative stress, and high energy demands than the hippocampus of AD cases.

“one study showed that the area surrounding NFTs in the hippocampus of AsymAD cases exhibits lower levels of proteins associated with inflammation, oxidative stress, and high energy demands than those in AD cases’ hippocampus [100].”

• cites [100] Walker JM, Kazempour Dehkordi S, Fracassi A, Vanschoiack A, Pavenko A, Taglialatela G et al (2022) Differential protein expression in the hippocampi of resilient individuals identified by digital spatial profiling. Acta Neuropathol Commun 10:23. https://doi.org/10.1186/s40478-022-01324-9 sourceSupported

Classified as probably not a substantial claim.

Aβ plaques create an environment that facilitates the rapid amplification of proteopathic tau seeds into large tau aggregates.

“Previous studies have demonstrated that Aβ plaques create a unique environment that facilitates the rapid amplification of proteopathic tau seeds into large tau aggregates, which initially appear in dystrophic neurites surrounding Aβ plaques (NP-tau), followed by the formation and spread of tau aggregates [34].”

• cites [34] He Z, Guo JL, McBride JD, Narasimhan S, Kim H, Changolkar L et al (2018) Amyloid-β plaques enhance Alzheimer’s brain tau-seeded pathologies by facilitating neuritic plaque tau aggregation. Nat Med 24:29–38. https://doi.org/10.1038/nm.4443 sourceSupported

Classified as probably not a substantial claim.

Tau aggregates initially appear in dystrophic neurites surrounding Aβ plaques (NP-tau) and subsequently spread.

“Previous studies have demonstrated that Aβ plaques create a unique environment that facilitates the rapid amplification of proteopathic tau seeds into large tau aggregates, which initially appear in dystrophic neurites surrounding Aβ plaques (NP-tau), followed by the formation and spread of tau aggregates [34].”

• cites [34] He Z, Guo JL, McBride JD, Narasimhan S, Kim H, Changolkar L et al (2018) Amyloid-β plaques enhance Alzheimer’s brain tau-seeded pathologies by facilitating neuritic plaque tau aggregation. Nat Med 24:29–38. https://doi.org/10.1038/nm.4443 sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing).

Microglial and astrocytic interactions with Aβ amyloid plaques are associated with amyloid plaque development and neuritic damage.

“Microglial and astrocytic interactions with Aβ amyloid plaques have been associated with amyloid plaque development and neuritic damage [81].”

• cites [81] Serrano-Pozo A, Muzikansky A, Gómez-Isla T, Growdon JH, Betensky RA, Frosch MP et al (2013) Differential relationships of reactive astrocytes and microglia to fibrillar amyloid deposits in Alzheimer disease. J Neuropathol Exp Neurol 72:462–471. https://doi.org/10.1097/NEN.0b013e3182933788 sourcePartly supported

  The Abstract (page not available) reports that both cell types are spatially associated with plaques, but only the microglial response increases with plaque size. The Discussion sections on microglial and astrocytic responses link microglia tentatively to plaque-size stabilization and astrocytes to plaque-associated neuritic damage. The study does not establish an association between both glial interactions and plaque development over time. (LLM, conf=0.82)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing).

Tau oligomers form prior to and independent of NFTs.

“Several groups have demonstrated that tau oligomers, which form prior to and independent of NFTs, are the toxic agents responsible for synaptic dysfunction in AD and drive cognitive decline [26, 49, 50, 58, 95].”

• cites [26] Fox LM, William CM, Adamowicz DH, Pitstick R, Carlson GA, Spires-Jones TL et al (2011) Soluble tau species, not neurofibrillary aggregates, disrupt neural system integration in a tau transgenic model. J Neuropathol Exp Neurol 70:588–595. https://doi.org/10.1097/NEN.0b013e318220a658 sourceCould not verify

  The Discussion reports that reducing a soluble tau species improved Arc responses despite persistent neurofibrillary pathology. It does not identify that species as tau oligomers or say when oligomers form relative to NFTs; searches for tau oligomers and formation before tangles found no such passage in our copy. (LLM, conf=0.76)

  Experimental — accuracy not yet measured
• cites [49] Lasagna-Reeves CA, Castillo-Carranza DL, Guerrero-Muñoz MJ, Jackson GR, Kayed R (2010) Preparation and characterization of neurotoxic tau oligomers. Biochemistry 49:10039–10041. https://doi.org/10.1021/bi1016233 sourceNot checked — no full text of the source
• cites [50] Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Guerrero-Munoz MJ, Kiritoshi T, Neugebauer V et al (2012) Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau. Sci Rep 2:700. https://doi.org/10.1038/srep00700 sourcePartly supported

  The Results (Brain-derived tau oligomers seeding and toxicity in vitro) report oligomers forming before detectable fibrils, and the isolation results describe brain-derived oligomers without paired helical filament contamination. These findings support oligomers as distinct from fibrillar tau, but do not establish that they form prior to NFTs in AD brains or independently of NFT formation in vivo. (LLM, conf=0.82)

  Experimental — accuracy not yet measured
• cites [58] Maeda S, Sahara N, Saito Y, Murayama S, Ikai A, Takashima A (2006) Increased levels of granular tau oligomers: an early sign of brain aging and Alzheimer’s disease. Neurosci Res 54:197–201. https://doi.org/10.1016/j.neures.2005.11.009 sourceNot checked — no full text of the source
• cites [95] Tian H, Davidowitz E, Lopez P, Emadi S, Moe J, Sierks M (2013) Trimeric tau is toxic to human neuronal cells at low nanomolar concentrations. Int J Cell Biol 2013:1–9. https://doi.org/10.1155/2013/260787 sourcePartly supported

  The Introduction (page unavailable) says oligomeric tau appears in early AD cytopathology and that synaptic dysfunction can occur before NFTs. It does not establish that tau oligomers themselves form before NFTs or that their formation is independent of NFTs. (LLM, conf=0.82)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing).

Elevated gene expression related to the early stages of autophagy is responsible for maintaining synaptic integrity through the efficient removal of tau oligomers in the hippocampus of AsymAD subjects.

“These findings align with a recent study in which elevated gene expression related to the early stages of autophagy was demonstrated to be responsible for maintaining synaptic integrity through the efficient removal of tau oligomers in the hippocampus of AsymAD subjects [98].”

• cites [98] Tumurbaatar B, Fracassi A, Scaduto P, Guptarak J, Woltjer R, Jupiter D et al (2023) Preserved autophagy in cognitively intact non-demented individuals with Alzheimer’s neuropathology. Alzheimers Dement. https://doi.org/10.1002/alz.13074 sourcePartly supported

  Section 3.2 (page unavailable) reports higher levels of early-autophagy proteins in NDAN hippocampi than in AD hippocampi. Section 3.4 reports a negative correlation between autophagy proteins and tau oligomers, while the Discussion proposes tau clearance as a protective mechanism. These findings do not demonstrate that elevated gene expression causes efficient tau-oligomer removal or thereby maintains synaptic integrity. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

Classified as probably not a substantial claim. May combine two claims.

Filamentous plaques are neurotoxic whereas compact dense-core plaques are relatively benign.

“Interestingly, it was previously reported that filamentous plaques are neurotoxic whereas compact dense-core plaques are relatively benign [38, 52].”

• cites [38] Huang Y, Happonen KE, Burrola PG, O’Connor C, Hah N, Huang L et al (2021) Microglia use TAM receptors to detect and engulf amyloid β plaques. Nat Immunol 22:586–594. https://doi.org/10.1038/s41590-021-00913-5 sourcePartly supported

  The Results section reports that markers of dystrophic neuronal membranes increased mainly around diffuse plaques, but also around dense-core plaques. The Discussion proposes that dense-core plaques may confine toxic Aβ oligomers; it does not establish that filamentous plaques are neurotoxic while compact plaques are relatively benign. No page numbers are available in our copy. (LLM, conf=0.84)

  Experimental — accuracy not yet measured
• cites [52] Lemke G, Huang Y (2022) The dense-core plaques of Alzheimer’s disease are granulomas. J Exp Med 219:e20212477. https://doi.org/10.1084/jem.20212477 sourcePartly supported

  The Introduction says Aβ oligomers and proto-fibrils that form diffuse plaques are mostly neurotoxic in vitro; it does not call those plaques “filamentous.” In “Implications of the granuloma hypothesis,” the authors suggest dense-core plaques may be less damaging than dispersed oligomers and proto-fibrils, but explicitly say the plaques are not beneficial. The claim turns that qualified comparison into a categorical statement that dense-core plaques are relatively benign. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing).

In the context of AD or aging, the formation of filamentous plaques has been associated with the phosphorylation of tau within dystrophic neurites.

“In the context of AD or aging, the formation of filamentous plaques has been associated with the phosphorylation of tau within dystrophic neuritis [13, 53, 106], which subsequently contributes to the formation of neuritic plaques (a subset of Aβ plaques surrounded by and containing dystrophic neurites) during AD progression”

• cites [13] Chen Y, Zhao S, Fan Z, Li Z, Zhu Y, Shen T et al (2021) Metformin attenuates plaque-associated tau pathology and reduces amyloid-β burden in APP/PS1 mice. Alzheimers Res Ther 13:40. https://doi.org/10.1186/s13195-020-00761-9 sourcePartly supported

  The Discussion (page unavailable) reports tau aggregation in dystrophic neurites surrounding Aβ plaques, and the Introduction reports enhanced tau phosphorylation in a mouse model with amyloid pathology. The paper does not establish that filamentous plaques form in association with this phosphorylation, nor does it extend that finding to aging generally. (LLM, conf=0.83)

  Experimental — accuracy not yet measured
• cites [53] Li T, Braunstein KE, Zhang J, Lau A, Sibener L, Deeble C et al (2016) The neuritic plaque facilitates pathological conversion of tau in an Alzheimer’s disease mouse model. Nat Commun 7:12082. https://doi.org/10.1038/ncomms12082 sourcePartly supported

  The Results section (‘Neuritic plaque is not sufficient for the conversion of tau’; page unavailable) reports that neuritic plaques in aging AD-model mice were associated with tau hyperphosphorylation within dystrophic neurites, and that phosphorylation was not observed before plaque formation. It does not identify these as ‘filamentous plaques’ or establish the association across AD or aging generally. (LLM, conf=0.82)

  Experimental — accuracy not yet measured
• cites [106] Yuan P, Condello C, Keene CD, Wang Y, Bird TD, Paul SM et al (2016) TREM2 haplodeficiency in mice and humans impairs the microglia barrier function leading to decreased amyloid compaction and severe axonal dystrophy. Neuron 90:724–739. https://doi.org/10.1016/j.neuron.2016.05.003 sourcePartly supported

  The Results section on tau hyperphosphorylation and axonal dystrophy reports phosphotau-positive dystrophic neurites around filamentous amyloid plaques in human AD brains. This supports the association in AD, but the paper does not establish it in aging apart from AD. (LLM, conf=0.83)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Microglia appear crucial to the initial appearance and structure of plaques and, following plaque formation, promote a chronic inflammatory state modulating neuronal gene expression changes in response to Aβ during AD pathology.

“In this context, microglia appear crucial to the initial appearance and structure of plaques and, following plaque formation, promote a chronic inflammatory state modulating neuronal gene expression changes in response to Aβ during AD pathology [84].”

• cites [84] Spangenberg E, Severson PL, Hohsfield LA, Crapser J, Zhang J, Burton EA et al (2019) Sustained microglial depletion with CSF1R inhibitor impairs parenchymal plaque development in an Alzheimer’s disease model. Nat Commun 10:3758. https://doi.org/10.1038/s41467-019-11674-z sourceSupported

Classified as probably not a substantial claim. May combine two claims.

Tau oligomers are the toxic agents responsible for synaptic dysfunction in AD and drive cognitive decline.

“Several groups have demonstrated that tau oligomers, which form prior to and independent of NFTs, are the toxic agents responsible for synaptic dysfunction in AD and drive cognitive decline [26, 49, 50, 58, 95].”

• cites [26] Fox LM, William CM, Adamowicz DH, Pitstick R, Carlson GA, Spires-Jones TL et al (2011) Soluble tau species, not neurofibrillary aggregates, disrupt neural system integration in a tau transgenic model. J Neuropathol Exp Neurol 70:588–595. https://doi.org/10.1097/NEN.0b013e318220a658 sourcePartly supported

  The Discussion (page not provided) reports that suppressing soluble tau expression rescued impaired hippocampal circuitry in a tau-transgenic mouse model despite persistent neurofibrillary pathology. The Introduction links soluble tau to memory impairment in those mice, but the paper does not identify tau oligomers as the toxic species or demonstrate that they cause synaptic dysfunction and cognitive decline in people with Alzheimer disease. (LLM, conf=0.88)

  Experimental — accuracy not yet measured
• cites [49] Lasagna-Reeves CA, Castillo-Carranza DL, Guerrero-Muñoz MJ, Jackson GR, Kayed R (2010) Preparation and characterization of neurotoxic tau oligomers. Biochemistry 49:10039–10041. https://doi.org/10.1021/bi1016233 sourceNot checked — no full text of the source
• cites [50] Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Guerrero-Munoz MJ, Kiritoshi T, Neugebauer V et al (2012) Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau. Sci Rep 2:700. https://doi.org/10.1038/srep00700 sourcePartly supported

  The Results sections on hippocampal long-term potentiation and pathological effects in vivo report impaired synaptic plasticity in brain slices and disrupted memory in mice after exposure to tau oligomers isolated from AD brains. These experiments support the proposed toxicity, but they do not establish that tau oligomers are the agents responsible for synaptic dysfunction or that they drive cognitive decline in people with AD. (LLM, conf=0.86)

  Experimental — accuracy not yet measured
• cites [58] Maeda S, Sahara N, Saito Y, Murayama S, Ikai A, Takashima A (2006) Increased levels of granular tau oligomers: an early sign of brain aging and Alzheimer’s disease. Neurosci Res 54:197–201. https://doi.org/10.1016/j.neures.2005.11.009 sourceNot checked — no full text of the source
• cites [95] Tian H, Davidowitz E, Lopez P, Emadi S, Moe J, Sierks M (2013) Trimeric tau is toxic to human neuronal cells at low nanomolar concentrations. Int J Cell Biol 2013:1–9. https://doi.org/10.1155/2013/260787 sourcePartly supported

  The Introduction reports that oligomeric tau induces synaptic dysfunction and that its levels correlate with memory loss in mice. It also describes oligomeric tau as implicated in AD progression, but does not establish that it is *the* agent responsible for synaptic dysfunction or that it drives cognitive decline in people with AD. The claim states those causal conclusions more firmly than the source does. (LLM, conf=0.87)

  Experimental — accuracy not yet measured

Classified as probably not a substantial claim.

HMW tau-containing particles are one of the predominant toxic entities.

“Our laboratory has recently demonstrated that the primary source of tau seeding activity in AD cases, corresponds to soluble high molecular weight (HMW) tau species; thus, HMW tau-containing particles are one of the predominant toxic entities [60].”

• cites [60] Martinez P, Patel H, You Y, Jury N, Perkins A, Lee-Gosselin A et al (2022) Bassoon contributes to tau-seed propagation and neurotoxicity. Nat Neurosci 25:1597–1607. https://doi.org/10.1038/s41593-022-01191-6 sourcePartly supported

  The Results section ‘BSN is associated with tau pathology in human tauopathy brain tissue’ (page unavailable) identifies the HMW fraction as having the strongest tau-seeding activity in AD patient brains. It does not establish that HMW tau-containing particles are predominant toxic entities; seeding activity alone does not demonstrate that ranking of toxicity. (LLM, conf=0.85)

  Experimental — accuracy not yet measured

Classified as probably not a substantial claim. May combine two claims.

Highly phosphorylated tau species in dystrophic neurites surrounding Aβ plaques (NP-Tau) aggregate faster and spread more widely than tau in NFTs.

“These highly phosphorylated tau species in dystrophic neurites surrounding Aβ plaques (NP-Tau) aggregate faster and spread more widely than tau in NFTs [34].”

• cites [34] He Z, Guo JL, McBride JD, Narasimhan S, Kim H, Changolkar L et al (2018) Amyloid-β plaques enhance Alzheimer’s brain tau-seeded pathologies by facilitating neuritic plaque tau aggregation. Nat Med 24:29–38. https://doi.org/10.1038/nm.4443 sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing).

Phagocytosis and endocytosis might underlie synaptic resilience in AsymAD individuals.

“previous evidence suggest that phagocytosis and endocytosis might underlie synaptic resilience in AsymAD individuals [92, 98].”

• cites [92] Tesi N, Van Der Lee SJ, Hulsman M, Jansen IE, Stringa N, Van Schoor NM et al (2020) Immune response and endocytosis pathways are associated with the resilience against Alzheimer’s disease. Transl Psychiatry 10:332. https://doi.org/10.1038/s41398-020-01018-7 sourcePartly supported

  The Discussion links immune response and endocytosis to escaping AD and suggests that dysregulation of these pathways may favor synapse engulfment. But the study examines cognitively healthy centenarians, not AsymAD individuals, and does not establish phagocytosis and endocytosis as mechanisms of synaptic resilience in that group. (LLM, conf=0.86)

  Experimental — accuracy not yet measured
• cites [98] Tumurbaatar B, Fracassi A, Scaduto P, Guptarak J, Woltjer R, Jupiter D et al (2023) Preserved autophagy in cognitively intact non-demented individuals with Alzheimer’s neuropathology. Alzheimers Dement. https://doi.org/10.1002/alz.13074 sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing).

Genetic variants linked to autophagy processes may contribute to resistance against amyloid plaques and NFTs in centenarians.

“Furthermore, genetic variants linked to autophagy processes may contribute to resistance against amyloid plaques and NFTs in centenarians [107]”

• cites [107] Zhang M, Ganz AB, Rohde S, Rozemuller AJM, Bank NB, Reinders MJT et al (2022) Resilience and resistance to the accumulation of amyloid plaques and neurofibrillary tangles in centenarians: an age-continuous perspective. Alzheimers Dement. https://doi.org/10.1002/alz.12899 sourceSupported

May combine two claims.

Microglia limit diffuse plaques by constructing and maintaining dense compact-like plaque properties in AD mouse models and humans, thereby blocking the progression of neuritic dystrophy and reducing tau phosphorylation in the local plaque environment.

“Furthermore, microglia limit diffuse plaques by constructing and maintaining dense compact-like plaque properties in AD mouse models and humans, thereby blocking the progression of neuritic dystrophy and reducing tau phosphorylation in the local plaque environment [12, 38, 106].”

• cites [12] Casali BT, MacPherson KP, Reed-Geaghan EG, Landreth GE (2020) Microglia depletion rapidly and reversibly alters amyloid pathology by modification of plaque compaction and morphologies. Neurobiol Dis 142:104956. https://doi.org/10.1016/j.nbd.2020.104956 sourcePartly supported

  Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

  Experimental — accuracy not yet measured
• cites [38] Huang Y, Happonen KE, Burrola PG, O’Connor C, Hah N, Huang L et al (2021) Microglia use TAM receptors to detect and engulf amyloid β plaques. Nat Immunol 22:586–594. https://doi.org/10.1038/s41590-021-00913-5 sourcePartly supported

  Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

  Experimental — accuracy not yet measured
• cites [106] Yuan P, Condello C, Keene CD, Wang Y, Bird TD, Paul SM et al (2016) TREM2 haplodeficiency in mice and humans impairs the microglia barrier function leading to decreased amyloid compaction and severe axonal dystrophy. Neuron 90:724–739. https://doi.org/10.1016/j.neuron.2016.05.003 sourcePartly supported

  Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

  Experimental — accuracy not yet measured

May combine two claims.

In AD cases, the tau species with the strongest seeding activity is a HMW tau in fraction 9 (> 2000 kDa), representing a small percentage of total tau in the brain.

“As we previously reported [60], the tau species with the strongest seeding activity in AD cases was a HMW tau in fraction 9 (> 2000 kDa) (Fig. 2e), representing a small percentage of the total tau in the brain (Fig. 2f).”

• cites [60] Martinez P, Patel H, You Y, Jury N, Perkins A, Lee-Gosselin A et al (2022) Bassoon contributes to tau-seed propagation and neurotoxicity. Nat Neurosci 25:1597–1607. https://doi.org/10.1038/s41593-022-01191-6 sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing).

The literature highlights the crucial involvement of ACTR2 and CFL1 in microglial motility.

“the literature also highlights their crucial involvement in microglial motility [18, 20].”

• cites [18] Desale SE, Chinnathambi S (2021) Phosphoinositides signaling modulates microglial actin remodeling and phagocytosis in Alzheimer’s disease. Cell Commun Signal 19:28. https://doi.org/10.1186/s12964-021-00715-0 sourcePartly supported

  The Background section, “Phosphatidylinositol signaling in microglial migration” (page unavailable), links ARP2/3-mediated actin polymerization to microglial migration, supporting the ACTR2 aspect at the complex level. It does not identify ACTR2 individually or establish a role for CFL1 in microglial motility; searches for CFL1 and cofilin found no such passage. (LLM, conf=0.83)

  Experimental — accuracy not yet measured
• cites [20] Drew J, Arancibia-Carcamo IL, Jolivet R, Lopez-Domenech G, Attwell D, Kittler JT (2020) Control of microglial dynamics by Arp2/3 and the autism and schizophrenia-associated protein Cyfip1. Neuroscience sourcePartly supported

  In ‘Inhibition of Arp2/3 and Rac1 leads to defects in surveillance of brain parenchyma’ (page unavailable), Arp2/3 inhibition reduced microglial surveillance by over 50%, supporting the motility point for the Arp2/3 complex. The paper does not establish a specific role for ACTR2 separately or address CFL1/cofilin; it also reports that chemotaxis was unaffected by Arp2/3 inhibition. (LLM, conf=0.86)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing).

This tau propagation could occur through axonal transmission to the neuronal soma and dendrites, ultimately leading to NFT formation.

“This tau propagation could occur through axonal transmission to the neuronal soma and dendrites, ultimately leading to NFT formation [34].”

• cites [34] He Z, Guo JL, McBride JD, Narasimhan S, Kim H, Changolkar L et al (2018) Amyloid-β plaques enhance Alzheimer’s brain tau-seeded pathologies by facilitating neuritic plaque tau aggregation. Nat Med 24:29–38. https://doi.org/10.1038/nm.4443 sourcePartly supported

  The Results section proposes that tau induced in dystrophic axons is transported retrogradely to neuronal somas, where it seeds NFT formation; the Discussion likewise suggests that neuritic-plaque tau may trigger NFTs in connected somas. Our copy does not specify transmission to dendrites, so that part of the claim is unsupported. No page number is available in the indexed passages. (LLM, conf=0.85)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing).

Aβ plaques create a unique environment that triggers tau phosphorylation within dystrophic neuritis in a mouse model of amyloidosis.

“In a mouse model of amyloidosis, it has been observed that Aβ plaques create a unique environment that triggers tau phosphorylation within dystrophic neuritis [53].”

• cites [53] Li T, Braunstein KE, Zhang J, Lau A, Sibener L, Deeble C et al (2016) The neuritic plaque facilitates pathological conversion of tau in an Alzheimer’s disease mouse model. Nat Commun 7:12082. https://doi.org/10.1038/ncomms12082 sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing).

CAP1 plays a role in facilitating the release of CFL1 from ADP-actin filaments.

“CAP1 plays a role in facilitating the release of CFL1 from ADP-actin filaments [29].”

• cites [29] Franco-Bocanegra McAuley, Nicoll B (2019) Molecular mechanisms of microglial motility: changes in ageing and Alzheimer’s disease. Cells 8:639. https://doi.org/10.3390/cells8060639 sourcePartly supported

  Section 3 (page unavailable) links CAP1 to CFL1 up-regulation during actin remodeling, supporting a role for CAP1 in CFL1 regulation. It does not say that CAP1 facilitates CFL1 release from ADP-actin filaments; searches for that mechanism found no such passage. (LLM, conf=0.78)

  Experimental — accuracy not yet measured

May combine two claims.

Reactive astrocytes and activated microglia respond differently to Aβ plaque formation; while microglia respond directly to the presence of plaques, astrocytes are associated with neuritic damage that occurs when synapses are already dysfunctional.

“One study showed that reactive astrocytes and activated microglia respond differently to Aβ plaque formation; while microglia respond directly to the presence of plaques, astrocytes are associated with neuritic damage that occurs when synapses are already dysfunctional [81].”

• cites [81] Serrano-Pozo A, Muzikansky A, Gómez-Isla T, Growdon JH, Betensky RA, Frosch MP et al (2013) Differential relationships of reactive astrocytes and microglia to fibrillar amyloid deposits in Alzheimer disease. J Neuropathol Exp Neurol 72:462–471. https://doi.org/10.1097/NEN.0b013e3182933788 sourcePartly supported

  Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing).

Actin network proteins in neurons play a crucial role in conferring resilience to AD.

“Interestingly, a recent study that used mass spectrometry-based proteomics has pointed out the crucial role of actin network proteins in neurons to confer resilience to AD [39].”

• cites [39] Huang Z, Merrihew GE, Larson EB, Park J, Plubell D, Fox EJ et al (2023) Brain proteomic analysis implicates actin filament processes and injury response in resilience to Alzheimer’s disease. Nat Commun 14:2747. https://doi.org/10.1038/s41467-023-38376-x sourcePartly supported

  The Results and Discussion associate actin filament processes with resilience to Alzheimer’s disease and relate actin dynamics to dendrite and synapse remodeling. But the Discussion says future studies must determine whether modulating these processes is necessary for resilience; the study does not establish that neuronal actin proteins confer it or play a crucial causal role. Page numbers are unavailable in our copy. (LLM, conf=0.87)

  Experimental — accuracy not yet measured

May combine two claims.

In regions lacking microglial processes, neuritic dystrophy is more severe, and these protective mechanisms are reduced during aging.

“Moreover, in regions lacking microglial processes, neuritic dystrophy is more severe, and these protective mechanisms are reduced during aging [15].”

• cites [15] Condello C, Yuan P, Schain A, Grutzendler J (2015) Microglia constitute a barrier that prevents neurotoxic protofibrillar Aβ42 hotspots around plaques. Nat Commun 6:6176. https://doi.org/10.1038/ncomms7176 sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Autophagy and microglial phagocytosis are impaired in AD and aged brains.

“Extensive evidence shows that autophagy and microglial phagocytosis are impaired in AD and aged brains [24, 30, 94, 103].”

• cites [24] Filippone A, Esposito E, Mannino D, Lyssenko N, Praticò D (2022) The contribution of altered neuronal autophagy to neurodegeneration. Pharmacol Ther 238:108178. https://doi.org/10.1016/j.pharmthera.2022.108178 sourcePartly supported

  The section on neuronal autophagy dysfunction in Alzheimer’s and Parkinson’s diseases reports impaired autophagy in people with AD, supporting that part of the claim. The Introduction discusses microglial activation, not impaired microglial phagocytosis; the retrieved passages also do not establish impairment of both processes in aged brains. Page numbers are unavailable in our copy. (LLM, conf=0.86)

  Experimental — accuracy not yet measured
• cites [30] Gabandé-Rodríguez E, Keane L, Capasso M (2020) Microglial phagocytosis in aging and Alzheimer’s disease. J Neurosci Res 98:284–298. https://doi.org/10.1002/jnr.24419 sourceNot checked — no full text of the source
• cites [94] Thomas AL, Lehn MA, Janssen EM, Hildeman DA, Chougnet CA (2022) Naturally-aged microglia exhibit phagocytic dysfunction accompanied by gene expression changes reflective of underlying neurologic disease. Sci Rep 12:19471. https://doi.org/10.1038/s41598-022-21920-y sourcePartly supported

  The Introduction links microglial phagocytic deficiencies to Alzheimer’s disease progression, and the Results and discussion (‘Loss of phagocytic capacity in microglia from aged mice’; page unavailable) report reduced Aβ uptake by microglia from aged mice. The paper does not report impaired autophagy in AD or aged brains; a search for ‘autophagy’ found the term only in a reference title. (LLM, conf=0.88)

  Experimental — accuracy not yet measured
• cites [103] Wang Z, Wang Q, Li S, Li X-J, Yang W, He D (2023) Microglial autophagy in Alzheimer’s disease and Parkinson’s disease. Front Aging Neurosci 14:1065183. https://doi.org/10.3389/fnagi.2022.1065183 sourceSupported

May combine two claims.

Reactive microglia encircle amyloid plaques and sequester Aβ amyloid within their cytoplasm in vitro.

“Initial observations revealed that reactive microglia encircle amyloid plaques and sequester Aβ amyloid within their cytoplasm in vitro [48, 104].”

• cites [48] Koenigsknecht-Talboo J, Landreth GE (2005) Microglial phagocytosis induced by fibrillar β-amyloid and IgGs are differentially regulated by proinflammatory cytokines. J Neurosci 25:8240–8249. https://doi.org/10.1523/JNEUROSCI.1808-05.2005 sourcePartly supported

  The Introduction (page unavailable) says activated microglia surround plaques in the Alzheimer’s disease brain. It does not place that observation in vitro; moreover, the Phagocytosis assay section (page unavailable) measures uptake of fluorescent microspheres after Aβ stimulation, not sequestration of Aβ within microglial cytoplasm. (LLM, conf=0.88)

  Experimental — accuracy not yet measured
• cites [104] Webster SD, Yang AJ, Margol L, Garzon-Rodriguez W, Glabe CG, Tenner AJ (2000) Complement component C1q modulates the phagocytosis of Aβ by microglia. Exp Neurol 161:127–138. https://doi.org/10.1006/exnr.1999.7260 sourceNot checked — no full text of the source

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

In human brains, CFL1 is expressed across various cell types, including astrocytes, neurons, and microglia, while ACTR2 is predominately expressed in microglia and macrophages.

“Indeed, in human brains, CFL1 is expressed across various cell types, including astrocytes, neurons, and microglia, while ACTR2 is predominately expressed in microglia and macrophages [108].”

• cites [108] Zhang Y, Sloan SA, Clarke LE, Caneda C, Plaza CA, Blumenthal PD et al (2016) Purification and characterization of progenitor and mature human astrocytes reveals transcriptional and functional differences with mouse. Neuron 89:37–53. https://doi.org/10.1016/j.neuron.2015.11.013 sourceCould not verify

  The Results section on acutely purified human brain cell transcriptomes describes expression profiles for these cell types, but does not report CFL1 or ACTR2 expression. Searches for both gene names and their proposed cell-type patterns found no passage in our copy that verifies the claim; no page numbers are available. (LLM, conf=0.72)

  Experimental — accuracy not yet measured

May combine two claims.

Pharmacological depletion of microglia in ten-month-old 5xFAD mice reduced the plaque burden, and the remaining plaques exhibited increased diffuse-like plaques and fewer compact-like shapes, together with increased dystrophic neuritis.

“Casali et al. showed that pharmacological depletion of microglia in ten-month-old 5xFAD mice reduced the plaque burden, and the remaining plaques exhibited increased diffuse-like plaques and fewer compact-like shapes, together with increased dystrophic neuritis [12].”

• cites [12] Casali BT, MacPherson KP, Reed-Geaghan EG, Landreth GE (2020) Microglia depletion rapidly and reversibly alters amyloid pathology by modification of plaque compaction and morphologies. Neurobiol Dis 142:104956. https://doi.org/10.1016/j.nbd.2020.104956 sourcePartly supported

  The Abstract reports reduced plaque burden, more diffuse-like and fewer compact-like plaques, and enhanced neuritic dystrophy after microglial depletion. But the Results state that Casali et al. treated 5xFAD mice at four months of age, not ten months. The Discussion contrasts their findings with a different study of ten-month-old mice that did not observe a plaque-burden change. Page numbers are not provided in our copy. (LLM, conf=0.91)

  Experimental — accuracy not yet measured

May combine two claims.

In addition to NFT deposition, there is a notable increase in tau oligomer-containing synapses within microglia and astrocytes during the early stages of AD but not in AsymAD cases.

“Moreover, a recent study demonstrated that in addition to NFT deposition, there is a notable increase in tau oligomer-containing synapses within microglia and astrocytes during the early stages of AD but not in AsymAD cases [89].”

• cites [89] Taddei RN, Perbet R, Mate De Gerando A, Wiedmer AE, Sanchez-Mico M, Connors Stewart T et al (2023) Tau oligomer-containing synapse elimination by microglia and astrocytes in Alzheimer disease. JAMA Neurol 80:1209. https://doi.org/10.1001/jamaneurol.2023.3530 sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing).

When human AD-derived tau was injected into a plaque-bearing 5xFAD mouse model, Aβ plaques facilitated the conversion and seeding of pathological tau in dystrophic neurites during the early stages of pathology.

“Furthermore, He et al. reported that when human AD-derived tau was injected into a plaque-bearing 5xFAD mouse model, Aβ plaques facilitated the conversion and seeding of pathological tau in dystrophic neurites during the early stages of pathology.”

• cites [34] He Z, Guo JL, McBride JD, Narasimhan S, Kim H, Changolkar L et al (2018) Amyloid-β plaques enhance Alzheimer’s brain tau-seeded pathologies by facilitating neuritic plaque tau aggregation. Nat Med 24:29–38. https://doi.org/10.1038/nm.4443 sourceSupported

May combine two claims.

Genetic ablation of tyrosine kinase TAM receptors inhibited microglial phagocytosis and decreased dense-core plaque density in the cortex and hippocampus after 12 months of age; these changes were not due to any changes in the production of Aβ peptides.

“Using the APP/PS1 AD mouse model, Huang et al. showed that genetic ablation of tyrosine kinase TAM receptors inhibited microglial phagocytosis and decreased dense-core plaque density in the cortex and hippocampus after 12 months of age; these changes were not due to any changes in the production of Aβ peptides [38].”

• cites [38] Huang Y, Happonen KE, Burrola PG, O’Connor C, Hah N, Huang L et al (2021) Microglia use TAM receptors to detect and engulf amyloid β plaques. Nat Immunol 22:586–594. https://doi.org/10.1038/s41590-021-00913-5 sourcePartly supported

  Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

  Experimental — accuracy not yet measured

Classified as probably not a substantial claim.

The ACTR2 (encoding ARP2) and CFL1 (Cofilin 1) genes play significant roles in actin remodeling, enabling both baseline movement (ruffling or branching) and chemotactic motility (migration).

“The ACTR2 (encoding ARP2) and CFL1 (Cofilin 1) genes play significant roles in actin remodeling, enabling both baseline movement (ruffling or branching) and chemotactic motility (migration) [18, 28, 29].”

• cites [18] Desale SE, Chinnathambi S (2021) Phosphoinositides signaling modulates microglial actin remodeling and phagocytosis in Alzheimer’s disease. Cell Commun Signal 19:28. https://doi.org/10.1186/s12964-021-00715-0 sourcePartly supported

  The Background sections on phosphatidylinositol signaling in microglial migration and actin remodeling (pages unavailable) link ARP2/3-mediated actin polymerization to membrane ruffling and migration toward chemoattractants. The passages do not identify ACTR2 or describe a role for CFL1/cofilin 1 in those processes, so they support only the ARP2/3 portion of the claim. (LLM, conf=0.85)

  Experimental — accuracy not yet measured
• cites [28] Franco-Bocanegra DK, George B, Lau LC, Holmes C, Nicoll JAR, Boche D (2019) Microglial motility in Alzheimer’s disease and after Aβ42 immunotherapy: a human post-mortem study. Acta Neuropathol Commun 7:174. https://doi.org/10.1186/s40478-019-0828-x sourcePartly supported

  The Introduction describes CFL1 as an actin-binding protein, links Arp2/3 to actin branching, and says actin reorganisation is essential to both baseline and directed microglial motility. It does not identify ACTR2 as the gene encoding ARP2 or establish a specific role for ACTR2 in those forms of movement; the Discussion says the Arp2/3 complex was not evaluated in this study. Page numbers are unavailable in our copy. (LLM, conf=0.85)

  Experimental — accuracy not yet measured
• cites [29] Franco-Bocanegra McAuley, Nicoll B (2019) Molecular mechanisms of microglial motility: changes in ageing and Alzheimer’s disease. Cells 8:639. https://doi.org/10.3390/cells8060639 sourceSupported

May combine two claims.

Exposure to ozone decreased the association of phagocytic microglia with amyloid plaques, impairing their ability to form a protective barrier and exacerbating dystrophic neuritis.

“In another study, exposure to ozone decreased the association of phagocytic microglia with amyloid plaques, impairing their ability to form a protective barrier and exacerbating dystrophic neuritis [33].”

• cites [33] Greve HJ, Dunbar AL, Lombo CG, Ahmed C, Thang M, Messenger EJ et al (2023) The bidirectional lung brain-axis of amyloid-β pathology: ozone dysregulates the peri-plaque microenvironment. Brain 146:991–1005. https://doi.org/10.1093/brain/awac113 sourceSupported

May combine two claims.

The plaque microenvironment in AsymAD individuals does not facilitate the formation of soluble tau species with strong seeding activity, unlike in neurotoxic tau oligomers formation in AD brains.

“Therefore, the evidence provided in the current study suggests that the plaque microenvironment in AsymAD individuals does not facilitate the formation of soluble tau species with strong seeding activity, unlike in neurotoxic tau oligomers formation in AD brains [60].”

• cites [60] Martinez P, Patel H, You Y, Jury N, Perkins A, Lee-Gosselin A et al (2022) Bassoon contributes to tau-seed propagation and neurotoxicity. Nat Neurosci 25:1597–1607. https://doi.org/10.1038/s41593-022-01191-6 sourcePartly supported

  The Results section on human tauopathy brain tissue reports strong seeding activity in high-molecular-weight tau from AD brains, supporting the AD side of the contrast. It describes those seeds as predominantly twisted filaments, not oligomers, and does not examine plaque microenvironments in AsymAD individuals. The AsymAD inference is framed as the citing authors’ own finding rather than a result attributed to this source. (LLM, conf=0.84)

  Experimental — accuracy not yet measured

May combine two claims.

In Trem2 or Dap12 haplodeficient mice and humans carrying the R47H mutation in the TREM2 gene, microglia demonstrate a markedly reduced ability to envelop amyloid deposits, decreasing compact plaque phenotypes and increasing amyloid fibril exposure to adjacent neurites, which is associated with tau hyperphosphorylation.

“In Trem2 or Dap12 haplodeficient mice and humans carrying the R47H mutation in the TREM2 gene, the microglia demonstrate a markedly reduced ability to envelop amyloid deposits, decreasing compact plaque phenotypes and increasing amyloid fibril exposure to adjacent neurites, which is associated with tau hyperphosphorylation [102, 106].”

• cites [102] Wang Y, Ulland TK, Ulrich JD, Song W, Tzaferis JA, Hole JT et al (2016) TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques. J Exp Med 213:667–675. https://doi.org/10.1084/jem.20151948 sourcePartly supported

  Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

  Experimental — accuracy not yet measured
• cites [106] Yuan P, Condello C, Keene CD, Wang Y, Bird TD, Paul SM et al (2016) TREM2 haplodeficiency in mice and humans impairs the microglia barrier function leading to decreased amyloid compaction and severe axonal dystrophy. Neuron 90:724–739. https://doi.org/10.1016/j.neuron.2016.05.003 sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing).

The absence of dementia in AsymAD individuals is partly due to synaptic preservation and, hence, neuron survival.

“It is well established that the absence of dementia in AsymAD individuals is partly due to synaptic preservation and, hence, neuron survival [31, 67].”

• cites [31] Gómez-Isla T, Frosch MP (2022) Lesions without symptoms: understanding resilience to Alzheimer disease neuropathological changes. Nat Rev Neurol 18:323–332. https://doi.org/10.1038/s41582-022-00642-9 sourcePartly supported

  In “Putative mechanisms of resilience > Neuronal and synaptic loss” (page not available), the review reports preserved synaptic markers and neuron numbers in people with AD pathology but no dementia. It says these findings favour identifying resilient brains by preservation of both neurons and synapses; it does not establish that synaptic preservation causes neuron survival, as the claim’s “hence” implies. (LLM, conf=0.86)

  Experimental — accuracy not yet measured
• cites [67] Neuner SM, Telpoukhovskaia M, Menon V, O’Connell KMS, Hohman TJ, Kaczorowski CC (2022) Translational approaches to understanding resilience to Alzheimer’s disease. Trends Neurosci 45:369–383. https://doi.org/10.1016/j.tins.2022.02.005 sourcePartly supported

  The “Features of resilient individuals” section reports preserved synaptic markers and neuron numbers in pathology-positive people without dementia, and the “Concluding remarks” identify maintained synapse structure as a contributor to resilience. The paper does not establish the claimed causal step that synaptic preservation leads to neuron survival; it reports the two forms of preservation together. Page numbers are unavailable in our copy. (LLM, conf=0.84)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing).

Effects of ARP2 from other cell types cannot be ruled out.

“therefore, we cannot rule out effects from other cell types [35, 85]”

• cites [35] Heinze A, Schuldt C, Khudayberdiev S, Van Bommel B, Hacker D, Schulz TG et al (2022) Functional interdependence of the actin regulators CAP1 and cofilin1 in control of dendritic spine morphology. Cell Mol Life Sci 79:558. https://doi.org/10.1007/s00018-022-04593-8 sourceCould not verify

  The Results section on CAP1 and dendritic spine morphology describes CAP1 deletion in cultured hippocampal neurons, not ARP2. Searches for ARP2 and for a caveat about effects from other cell types found no passage in our copy addressing that claim; no page numbers are available. (LLM, conf=0.75)

  Experimental — accuracy not yet measured
• cites [85] Spence EF, Kanak DJ, Carlson BR, Soderling SH (2016) The Arp2/3 complex is essential for distinct stages of spine synapse maturation, including synapse unsilencing. J Neurosci 36:9696–9709. https://doi.org/10.1523/JNEUROSCI.0876-16.2016 sourceCould not verify

  The synapse-unsilencing section says the sparse-transfection experiments predominantly reflect postsynaptic ArpC3 loss in neurons receiving WT input. It does not discuss whether effects of Arp2/3 from other cell types can or cannot be ruled out. Searches for other cell types and non-cell-autonomous contributions found no passage addressing that limitation; page numbers were unavailable in our copy. (LLM, conf=0.69)

  Experimental — accuracy not yet measured

May combine two claims.

Microglia surrounding Aβ plaques in NDAN are hyperactive and more effectively recognize damaged synapses with greater phagocytic capacity than microglia in AD.

“concluding that microglia surrounding Aβ plaques in NDAN are hyperactive and more effectively recognize damaged synapses with greater phagocytic capacity than microglia in AD [27].”

• cites [27] Fracassi A, Marcatti M, Tumurbaatar B, Woltjer R, Moreno S, Taglialatela G (2023) TREM2 -induced activation of microglia contributes to synaptic integrity in cognitively intact aged individuals with Alzheimer’s neuropathology. Brain Pathol. https://doi.org/10.1111/bpa.13108 sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing).

CFL1 is one of the main components of actin/cofilin rods, which are insoluble aggregates that lead to neurodysfunction.

“CFL1 is one of the main components of actin/cofilin rods, which are insoluble aggregates that lead to neurodysfunction [4, 101].”

• cites [4] Bamburg JR, Bernstein BW, Davis RC, Flynn KC, Goldsbury C, Jensen JR et al (2010) ADF/cofilin-actin rods in neurodegenerative diseases. Curr Alzheimer Res 7:241–250. https://doi.org/10.2174/156720510791050902 sourcePartly supported

  The “Isolation and characterization of rods” section identifies cofilin-1 as a core rod component, and “Cofilin-actin rods form in neurites and block vesicular transport and distal synaptic activity” links rods to neuronal dysfunction (page numbers unavailable). The copy describes rods as aggregated actin filaments but does not establish that they are insoluble; it says isolated rods are not stable in non-ionic detergents. (LLM, conf=0.88)

  Experimental — accuracy not yet measured
• cites [101] Wang Q, Yuan W, Yang X, Wang Y, Li Y, Qiao H (2020) Role of cofilin in Alzheimer’s disease. Front Cell Dev Biol 8:584898. https://doi.org/10.3389/fcell.2020.584898 sourcePartly supported

  The Introduction identifies CFL1 as the gene encoding cofilin-1, and the Cofilin-Actin Rods section describes rods containing ADF/cofilin and actin in a 1:1 ratio. That section calls them rod-shaped filament bundles, but does not establish that they are insoluble aggregates or that the rods themselves cause neuronal dysfunction; the Conclusion discusses dysfunction involving cofilin more generally. Page numbers are unavailable in our copy. (LLM, conf=0.82)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing).

Cytoskeleton reorganization is necessary to carry out these processes.

“At the molecular level, cytoskeleton reorganization is necessary to carry out these processes [29].”

• cites [29] Franco-Bocanegra McAuley, Nicoll B (2019) Molecular mechanisms of microglial motility: changes in ageing and Alzheimer’s disease. Cells 8:639. https://doi.org/10.3390/cells8060639 sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing).

ARP2 is not expressed solely in microglia.

“It is worth to mention that ARP2 is not expressed solely in microglia; therefore, we cannot rule out effects from other cell types [35, 85].”

• cites [35] Heinze A, Schuldt C, Khudayberdiev S, Van Bommel B, Hacker D, Schulz TG et al (2022) Functional interdependence of the actin regulators CAP1 and cofilin1 in control of dendritic spine morphology. Cell Mol Life Sci 79:558. https://doi.org/10.1007/s00018-022-04593-8 sourceCould not verify

  The Results section reports CAP1 expression in mouse neurons and dendritic spines, not ARP2 expression. Searches for ARP2 with microglia and for Arp2/3 in neurons found no passage in our copy addressing whether ARP2 is expressed outside microglia. No page numbers were provided for these passages. (LLM, conf=0.76)

  Experimental — accuracy not yet measured
• cites [85] Spence EF, Kanak DJ, Carlson BR, Soderling SH (2016) The Arp2/3 complex is essential for distinct stages of spine synapse maturation, including synapse unsilencing. J Neurosci 36:9696–9709. https://doi.org/10.1523/JNEUROSCI.0876-16.2016 sourceSupported

Classified as probably not a substantial claim.

In a transgenic mouse model of AD, efficient microglial clustering around Aβ plaques mitigates amyloid-driven tau seeding.

“Considering a previous study in a transgenic mouse model of AD demonstrating that efficient microglial clustering around Aβ plaques mitigates amyloid-driven tau seeding [32]”

• cites [32] Gratuze M, Chen Y, Parhizkar S, Jain N, Strickland MR, Serrano JR et al (2021) Activated microglia mitigate Aβ-associated tau seeding and spreading. J Exp Med 218:e20210542. https://doi.org/10.1084/jem.20210542 sourcePartly supported

  The Conclusion reports that microglial depletion or TREM2 deficiency increased Aβ-associated tau pathology, supporting a protective role for microglia. But the Introduction and Abstract state that repopulated microglia clustered around plaques yet showed elevated tau seeding and spreading. The paper therefore supports protection by appropriately activated microglia, not clustering alone. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing).

There is no clear evidence of CFL1 and CAP1 changes in AD.

“Although there is no clear evidence of CFL1 and CAP1 changes in AD [28, 72],”

• cites [28] Franco-Bocanegra DK, George B, Lau LC, Holmes C, Nicoll JAR, Boche D (2019) Microglial motility in Alzheimer’s disease and after Aβ42 immunotherapy: a human post-mortem study. Acta Neuropathol Commun 7:174. https://doi.org/10.1186/s40478-019-0828-x sourcePartly supported

  The Results section (Microglial motility-related proteins; page not provided) reports no significant difference in CFL1 between AD cases and controls. The four proteins examined were Iba1, CFL1, P2RY12 and CORO1A, not CAP1, so this paper does not support the CAP1 part of the claim. (LLM, conf=0.88)

  Experimental — accuracy not yet measured
• cites [72] Pelucchi S, Vandermeulen L, Pizzamiglio L, Aksan B, Yan J, Konietzny A et al (2020) Cyclase-associated protein 2 dimerization regulates cofilin in synaptic plasticity and Alzheimer’s disease. Brain Commun 2:fcaa086. https://doi.org/10.1093/braincomms/fcaa086 sourcePartly supported

  The Results section, “Synaptic localization of CAP2 and cofilin is impaired in Alzheimer’s disease hippocampi” (page unavailable), reports no change in CAP1 total levels in the hippocampus or superior frontal gyrus of AD patients. It also reports a significant increase in hippocampal synaptic cofilin levels, so the broad claim that there is no clear evidence of cofilin/CFL1 changes is not supported, although total cofilin levels were unchanged. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

May combine two claims.

ARP2, CAP1, and CFL1 are proteins related to engulfment processes through actin-based motility mechanisms, and were recently associated with AD resilience according to protein coexpression analysis.

“In this context, ARP2, CAP1, and CFL1 are proteins related to engulfment processes through actin-based motility mechanisms [28, 29], that were recently associated with AD resilience according to protein coexpression analysis [39].”

• cites [28] Franco-Bocanegra DK, George B, Lau LC, Holmes C, Nicoll JAR, Boche D (2019) Microglial motility in Alzheimer’s disease and after Aβ42 immunotherapy: a human post-mortem study. Acta Neuropathol Commun 7:174. https://doi.org/10.1186/s40478-019-0828-x sourcePartly supported

  The Introduction (page not provided) describes Arp2/3 and CFL1 as involved in actin organization and links actin-based microglial structures to migration and phagocytosis. It does not identify CAP1 or establish its role in engulfment. The AD-resilience finding is attributed to a different citation, [39], so it is not judged against this source. (LLM, conf=0.87)

  Experimental — accuracy not yet measured
• cites [29] Franco-Bocanegra McAuley, Nicoll B (2019) Molecular mechanisms of microglial motility: changes in ageing and Alzheimer’s disease. Cells 8:639. https://doi.org/10.3390/cells8060639 sourceSupported
• cites [39] Huang Z, Merrihew GE, Larson EB, Park J, Plubell D, Fox EJ et al (2023) Brain proteomic analysis implicates actin filament processes and injury response in resilience to Alzheimer’s disease. Nat Commun 14:2747. https://doi.org/10.1038/s41467-023-38376-x sourcePartly supported

  The Results sections on protein co-expression and M5 enrichment associate an actin-filament-related protein module with resilience to Alzheimer’s disease. They do not identify ARP2, CAP1, or CFL1 as the proteins associated with resilience; the named resilience-associated actin-related protein is CAPG, not CAP1. The engulfment-mechanism clause is attached to other citations and is not assessed here. (LLM, conf=0.85)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing).

Aging reduces microglial adhesion and migration toward fibrillar Aβ in APP/PS1 mice and even in wild-type mice.

“It has been shown that aging reduces microglial adhesion and migration toward fibrillar Aβ in APP/PS1 mice and even in wild-type mice [23].”

• cites [23] Fang Y, Wang J, Yao L, Li C, Wang J, Liu Y et al (2018) The adhesion and migration of microglia to β-amyloid (Aβ) is decreased with aging and inhibited by Nogo/NgR pathway. J Neuroinflammation 15:210. https://doi.org/10.1186/s12974-018-1250-1 sourceSupported

Classified as probably not a substantial claim.

Microglial function is highly dependent on baseline motility, which consists of the extension, retraction, and movement of microglial processes, allowing membrane ruffling.

“Microglial function is highly dependent on baseline motility, which consists of the extension, retraction, and movement of microglial processes [37, 70], allowing membrane ruffling.”

• cites [37] Hristovska I, Pascual O (2016) Deciphering resting microglial morphology and process motility from a synaptic prospect. Front Integr Neurosci. https://doi.org/10.3389/fnint.2015.00073 sourcePartly supported

  The Introduction (page unavailable) defines microglial motility as the continual extension and retraction of processes while the soma remains stationary. It says rapid process motility could be compatible with certain synaptic functions, but does not establish that microglial function is highly dependent on baseline motility. The Role of Purines section reports membrane ruffling after ATP signaling in vitro, not as a general consequence of baseline motility. (LLM, conf=0.84)

  Experimental — accuracy not yet measured
• cites [70] Parkhurst CN, Gan W-B (2010) Microglia dynamics and function in the CNS. Curr Opin Neurobiol 20:595–600. https://doi.org/10.1016/j.conb.2010.07.002 sourcePartly supported

  The section 'Baseline microglial dynamics and rapid process extension' describes constant movement of microglial processes and reports process extension and retraction. But it says the functional significance of baseline motility remains unknown, so it does not establish that microglial function is highly dependent on it. The cited text also does not describe membrane ruffling. (LLM, conf=0.87)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing).

Genetic variants of genes related to autophagy functions are involved in resilience against AD neuropathology.

“However, it has been reported that genetic variants of genes related to autophagy functions are involved in resilience against AD neuropathology [82, 92, 107].”

• cites [82] Seto M, Weiner RL, Dumitrescu L, Hohman TJ (2021) Protective genes and pathways in Alzheimer’s disease: moving towards precision interventions. Mol Neurodegener 16:29. https://doi.org/10.1186/s13024-021-00452-5 sourceSupported
• cites [92] Tesi N, Van Der Lee SJ, Hulsman M, Jansen IE, Stringa N, Van Schoor NM et al (2020) Immune response and endocytosis pathways are associated with the resilience against Alzheimer’s disease. Transl Psychiatry 10:332. https://doi.org/10.1038/s41398-020-01018-7 sourcePartly supported

  The Discussion (page unavailable) associates genetic variants in immune-response and endocytosis pathways with resilience against AD in cognitively healthy centenarians. Autophagy was not among the five pathways studied, and resilience was assessed through avoidance of AD rather than resistance to measured AD neuropathology. Those specific parts of the claim are not supported by this paper. (LLM, conf=0.84)

  Experimental — accuracy not yet measured
• cites [107] Zhang M, Ganz AB, Rohde S, Rozemuller AJM, Bank NB, Reinders MJT et al (2022) Resilience and resistance to the accumulation of amyloid plaques and neurofibrillary tangles in centenarians: an age-continuous perspective. Alzheimers Dement. https://doi.org/10.1002/alz.12899 sourcePartly supported

  The Discussion (page unavailable in our copy) links protective variants associated with autophagy to centenarians’ cognitive health despite AD neuropathology. It proposes that genetically defined resilience may explain this observation; it does not establish that autophagy-related variants are involved in that resilience. (LLM, conf=0.82)

  Experimental — accuracy not yet measured

May combine two claims.

48 DEGs in plaque-AsymAD and 9 DEGs in plaque-AD were previously linked to AD targets through RNA-seq, proteomic, and metabolomic studies.

“Furthermore, 48 DEGs in plaque-AsymAD and 9 DEGs in plaque-AD were previously linked to AD targets through RNA-seq, proteomic, and metabolomic studies.”

• cites [109] Agora: an open platform for exploration of Alzheimer’s disease evidenceNot matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

There is a trend toward decreased overall GFAP coverage in AsymAD cases compared with AD cases, but it is not significant.

“A trend toward increased overall IBA1 and decreased overall GFAP coverage in AsymAD cases was observed, although the difference was not significant (Fig. 3b, e).”

May combine two claims.

There is a trend toward increased overall IBA1 coverage in AsymAD cases compared with AD cases, but it is not significant.

“A trend toward increased overall IBA1 and decreased overall GFAP coverage in AsymAD cases was observed, although the difference was not significant (Fig. 3b, e).”

May combine two claims.

From the 813 upregulated genes in plaque-AsymAD ROIs, 57 DEGs were in endocytic-, autophagy- and phagocytic-related pathways; in contrast, only 12 DEGs out of the 986 upregulated genes in plaque-AD ROIs belonged to these pathways.

“From the 813 upregulated genes in the plaque-AsymAD ROIs, 57 DEGs were in the endocytic-, autophagy- and phagocytic-related pathways. In contrast, only 12 DEGs out of the 986 upregulated genes in plaque-AD ROIs belonged to these pathways (Fig. 4c and Supplementary Excel 2).”

The quote only partly states this claim.

GFAP levels are decreased in intermediate plaques in AsymAD MFGs compared with AD MFGs.

“whereas GFAP levels were decreased in intermediate plaques (Fig. 3f).”

Probably not a substantial claim: may not pass S3 (load-bearing).

The three previously classified amyloid plaques were positive for Aβ-amyloid using 6E10 and 4G8 anti-Aβ-amyloid antibodies.

“Using the 6E10 and 4G8 anti-Aβ-amyloid antibodies, we confirmed that the three previously classified amyloid plaques were positive for Aβ-amyloid (Supplementary Fig. 3).”

May combine two claims.

A total of 1799 DEGs were identified; 813 were upregulated in the Aβ plaque microenvironment of AsymAD (plaque-AsymAD), while 986 were upregulated in AD (plaque-AD).

“We identified a total of 1799 DEGs. Among these genes, 813 were upregulated in the Aβ plaque microenvironment of AsymAD (plaque-AsymAD), while 986 were upregulated in AD (plaque-AD) (Fig. 4b and Supplementary Excel 1).”

May combine two claims.

Mean ARP2 immunoreactivity is increased in the IBA1-positive area of the AsymAD plaque microenvironment, indicating elevated ARP2 levels in microglia surrounding amyloid plaques in AsymAD MFGs compared to AD MFGs.

“Furthermore, the mean of ARP2 immunoreactivity increased when evaluating only the IBA1-positive (IBA1+) area of the AsymAD plaque microenvironment. This indicates elevated ARP2 levels in microglia surrounding the amyloid plaques in AsymAD MFGs compared to AD MFGs (Fig. 5c).”

Probably not a substantial claim: may not pass S3 (load-bearing).

The increase in CAP1 levels was not statistically significant between conditions when overall intensity was determined.

“This increase in CAP1 levels was not statistically significant between conditions when overall intensity was determined (Fig. 5g);”

May combine two claims.

The two mechanisms of efficient actin-based microglial motility and decreased tau seeding can potentially protect against the toxic cascade initiated by Aβ, preserving brain health and slowing AD pathology progression.

“These two mechanisms can potentially protect against the toxic cascade initiated by Aβ, preserving brain health, and slowing AD pathology progression.”

Probably not a substantial claim: may not pass S3 (load-bearing).

AsymAD brains show larger nuclei and cellular sizes than age-matched healthy controls.

“even show larger nuclei and cellular sizes than age-matched healthy controls [79].”

• cites [79] Riudavets MA, Iacono D, Resnick SM, O’Brien R, Zonderman AB, Martin LJ et al (2007) Resistance to Alzheimer’s pathology is associated with nuclear hypertrophy in neurons. Neurobiol Aging 28:1484–1492. https://doi.org/10.1016/j.neurobiolaging.2007.05.005 sourceNot checked — no full text of the source

Probably not a substantial claim: may not pass S3 (load-bearing).

Chronic traumatic encephalopathy (CTE) was not reported for any of these cases.

“Chronic traumatic encephalopathy (CTE) was not reported for any of these cases.”

Classified as probably not a substantial claim.

AD and AsymAD cases were selected according to age, NFTs Braak stages, Thal stage, and TDP43/LATE status.

“AD and AsymAD cases were selected according to age (mean [SD], 82.68 [10.4] years in AD cases and 88.15 [5.5] years in AsymAD cases), NFTs Braak stages (5.32 [0.82] in AD cases and 4.62 [0.76] in AsymAD cases), Thal stage (4.72 [0.75] in AD cases and 4.25[0.45] in AsymAD cases) and TDP43/LATE status (0.94 [0.94] in AD cases and 0.54 [0.82] in AsymAD cases).”

Probably not a substantial claim: may not pass S3 (load-bearing).

For GeoMx HuWTA analyses, p values were adjusted for multiple analyses using the Benjamini-Hochberg procedure with a false discovery rate (FDR) of 0.01.

“For GeoMx HuWTA analyses, the p values were adjusted for multiple analyses using the Benjamini–Hochberg procedure with a false discovery rate (FDR) of 0.01.”

Probably not a substantial claim: may not pass S3 (load-bearing).

All subjects received their last clinical evaluation within 15 months before death.

“All subjects received their last clinical evaluation within 15 months before death.”

Probably not a substantial claim: may not pass S3 (load-bearing).

None of the control individuals or AD or AsymAD cases exhibited Lewy bodies in the examined sections.

“None of the control individuals or AD or AsymAD cases exhibited Lewy bodies in the examined sections.”

May combine two claims.

The upregulation of actin-based motility genes potentially heightens membrane dynamics, facilitating efficient migration toward the vicinity of the plaque and promoting the elongation of microglial branches, enhancing their engagement with the plaque.

“This upregulation potentially heightens membrane dynamics, facilitating efficient migration toward the vicinity of the plaque and promoting the elongation of microglial branches, enhancing their engagement with the plaque.”

Probably not a substantial claim: may not pass S3 (load-bearing).

Data collection and analyses were performed by a researcher blinded to the experimental conditions.

“Data collection and analyses were performed by a researcher blinded to the experimental conditions.”

May combine two claims.

Although both AsymAD and AD cases exhibit neuritic plaques, the dystrophic neuritic component induced by tau is notably more pronounced in AD cases.

“indicating that although both AsymAD and AD cases exhibit neuritic plaques, the dystrophic neuritic component induced by tau is notably more pronounced in AD cases.”

May combine two claims.

A stronger microglial barrier surrounding plaques in the cortices of AsymAD cases may protect against synaptic derangement and neuritic damage, which, in turn, could mitigate the astrocytic response.

“Therefore, a stronger microglial barrier surrounding plaques in the cortices of AsymAD cases may protect against synaptic derangement and neuritic damage, which, in turn, could mitigate the astrocytic response.”

Probably not a substantial claim: may not pass S3 (load-bearing).

Neuronal degeneration in AD could occur via non-NFT formation in multiple neurons.

“Interestingly, it has been reported that neuronal degeneration in AD could occur via non-NFT formation in multiple neurons [44].”

• cites [44] Ihara Y (2001) PHF and PHF-like fibrils–cause or consequence? Neurobiol Aging 22:123–126. https://doi.org/10.1016/S0197-4580(00)00200-1 sourceNot checked — no full text of the source

Probably not a substantial claim: may not pass S3 (load-bearing).

Microglia around plaques are key regulators of their morphology in AD mouse models.

“Substantial evidence suggests that microglia around plaques are key regulators of their morphology in AD mouse models.”

May combine two claims.

Microglia are potentially critical regulators of plaque conformation and dense-core Aβ plaques do not form spontaneously but are constructed from loosely organized Aβ material produced by phagocytic microglia.

“These findings suggest that microglia are potentially critical regulators of plaque conformation and that dense-core Aβ plaques do not form spontaneously but are constructed from loosely organized Aβ material produced by phagocytic microglia.”

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

ARP2 is part of the Arp2/3 complex, and its role is to engage with actin monomers to start the formation of a new filament branch.

“While ARP2 (Actin related protein 2) is part of the Arp2/3 complex, and its role is to engage with actin monomers to start the formation of a new filament branch [75]”

• cites [75] Pollard TD, Beltzner CC. Structure and function of the Arp2/3 complexNot matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

Probably not a substantial claim: may not pass S4 (based). May combine two claims.

These genes potentially facilitate the deposition of Aβ into dense-core plaques and prevent amyloid-driven tau pathogenesis within the amyloid plaque microenvironment of filamentous plaques.

“These genes potentially facilitate the deposition of Aβ into dense-core plaques and prevent amyloid-driven tau pathogenesis within the amyloid plaque microenvironment of filamentous plaques.”

May combine two claims.

In AsymAD cases, microglia exhibit more efficient actin-based motility mechanisms, which could heighten actin dynamics, facilitating efficient migration toward the vicinity of the plaque, promoting the elongation of microglial branches, and enhancing engagement with the plaque.

“Overall, these data suggest that in AsymAD cases, microglia exhibit more efficient actin-based motility mechanisms, which could heighten actin dynamics, facilitating efficient migration toward the vicinity of the plaque, promoting the elongation of microglial branches, and enhancing engagement with the plaque.”

Probably not a substantial claim: may not pass S3 (load-bearing).

AsymAD brains may possess the ability to increase ARP2 expression in response to amyloid pathology.

“Furthermore, AsymAD brains may possess the ability to increase ARP2 expression in response to amyloid pathology.”

May combine two claims.

Increased microglial chemotactic motility in AsymAD could allow microglia to remodel their branches and surround the amyloid plaque, facilitating the engulfment and clearance of toxic Aβ aggregates.

“These could allow microglia to remodel their branches and surround the amyloid plaque, facilitating the engulfment and clearance of toxic Aβ aggregates”

May combine two claims.

This may mitigate Aβ-associated tau pathogenesis and decrease tau seeding.

“which may mitigate Aβ-associated tau pathogenesis and decrease tau seeding”

May combine two claims.

Microglia with enhanced migration and extension toward newly formed amyloid plaques could reduce the effect of amyloid in promoting tau seeding and subsequently mitigate synaptic deterioration.

“This ability of microglia to efficiently cluster around plaques could reduce the effect of amyloid in promoting tau seeding and subsequently mitigate synaptic deterioration.”

Probably not a substantial claim: may not pass S3 (load-bearing).

The findings are limited to the middle frontal gyrus brain area.

“Furthermore, our findings are limited to the middle frontal gyrus brain area, and this limitation should be considered when interpreting the data.”